GlassScriptPhysician profile
Mark S Luedke
NPI 1316915481
$5,886.81
in general payments reported to CMS, 2019-2025
21 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $643 · 2021: $1,655 · 2022: $1,075 · 2023: $522 · 2024: $536 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Entertainment: $43.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.00 |
| Entertainment | $43.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,214.62 | 2019-2025 | Biofinity Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $803.57 | 2019-2025 | Acrysof Iq Vivity, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $496.96 | 2022-2024 | Infuse, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $383.60 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $379.68 | 2021-2022 | |
| Shire North American Group INC | $302.08 | 2019 | |
| Abb Con-Cise Optical Group LLC | $293.26 | 2019-2024 | Spectacle Lenses, Contact Lens |
| Johnson & Johnson Vision Care, INC. | $199.16 | 2019-2023 | Acuvue |
| Optos, INC. | $151.24 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $116.57 | 2022 | |
| Dompe US, INC. | $113.14 | 2024 | Oxervate |
| Optovue, INC. | $92.59 | 2019 | |
| Lkc Technologies, INC. | $90.72 | 2024 | |
| Alcon Research LLC | $86.86 | 2019 | |
| Kala Pharmaceuticals, INC. | $46.16 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $34.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.70 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $17.38 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Visioneering Technologies, INC. | $7.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Luedke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.